Researchers at the University of Manchester, UK, are testing a secret herb in a bid to stop the severe hot flushes that besiege breast cancer patients on hormone treatment. Professor Alex Molassiotis, of the School of Nursing, Midwifery and Social Work, says the herb - one of the mint family, found in...
Herb Tested To Stop Breast Cancer Patients’ Hot Flushes And Night Sweats
Commission Welcomes Changes To EU Law To Allow Export Of Patented Medicine To Countries In Need
The European Commission today welcomes the adoption by the European Council of a regulation allowing companies to produce copies of patented medicines under license for export to “countries in need” without sufficient capacity to produce them. The regulation implements within the EU the necessary...
Canadian Health Minister Clement Notes Progress At G8 Health Ministers Meeting
Canadian Health Minister Tony Clement was pleased with the outcome of discussions at the first-ever meeting of G8 Health Ministers in Moscow. Ministers renewed their international commitment to combat avian influenza and prevent and prepare for a possible human pandemic influenza. They also committed...
Foundation Trust Network Responds To New Wave Of FT Authorisations, UK
Sue Slipman, Director of the Foundation Trust Network said: “The authorisation of the first wave of mental health foundation trusts is great news. “It marks a new era for mental health which, for the first time, will have its funding put on a more secure footing through legally binding contracts...
1,000 New York City Doctors Will Get Electronic Health Records Systems
Mayor Michael R. Bloomberg and Department of Health and Mental Hygiene (DOHMH) Commissioner Thomas R. Frieden today fulfilled a pledge from the Mayor’s campaign and State of the City by announcing that the City has appropriated $27 million to help provide 1,000 New York City Doctors with electronic...
Positive Phase II Results With Orally Active GnRH Receptor Antagonist In Endometriosis - Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive results of its ‘proof of concept’, safety, efficacy and dose-finding Phase II clinical trial using its proprietary, orally-active small molecule Gonadotropin-Releasing Hormone (GnRH) receptor antagonist (NBI-56418). The...
Clinical Utility Of Two Novel Genes That Can Identify Patients At Higher Risk For Early Breast Cancer Recurrence
AviaraDx, Inc., formerly known as Arcturus Bioscience, Inc., a leader in molecular cancer profiling, announced today that a study, conducted in collaboration with Mayo Clinic, demonstrated the clinical utility of two novel genes that can identify patients at higher risk for early breast cancer recurrence...
Pharmacokinetic Data For Nastech’s Intranasal Parathyroid Hormone (PTH1-34) Demonstrated Similar Profile To Approved Injectable Product
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) presents data today from a Phase I pharmacokinetic study of Parathyroid Hormone (PTH1-34) nasal spray demonstrating a similar pharmacokinetic profile to the approved subcutaneous product, Forteo(R) (teriparatide). The data are being presented at the...
Abbott’s HUMIRA(R) (Adalimumab) Receives Positive Opinion From European Medicines Agency For The Treatment Of Ankylosing Spondylitis
Abbott today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), granted a positive opinion recommending approval of HUMIRA(R) (adalimumab) for the treatment of severe active ankylosing spondylitis. The positive opinion...
Abbott’s New Tablet Formulation Of Kaletra(R) (Lopinavir/Ritonavir) Receives Positive Opinion From The European Medicines Agency
Abbott announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued a positive opinion recommending approval of a new, more convenient tablet formulation of its protease inhibitor (PI) Kaletra(R) (lopinavir/ritonavir)....